文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

HIV感染者MSM人群接种九价HPV疫苗的IV期开放标签单臂多中心临床试验

A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017.
PubMed 文献 · Clin Infect Dis · 2026-01-01

这项IV期开放标签单臂多中心试验评估了9vHPV疫苗在16-35岁HIV感染的MSM中的免疫原性、安全性及年龄和CD4/CD8比值的影响。158例入组、138例完成符合方案分析,第96周时九个基因型血清转换率均超过85%,疫苗型别新发感染率为24%(以HPV-16为主),高危型清除率74%。疫苗免疫原性稳健且无严重不良事件,支持在该高危人群中将接种年龄扩展至26岁以上。

要点

  • 9vHPV疫苗在HIV感染的MSM中第96周四价基因型血清转换率均超过85%
  • 疫苗包含型别新发感染24%(以HPV-16为主),高危型清除率74%
  • 年龄≥26岁、CD4/CD8比值、最低CD4或CD4计数均不影响免疫原性

核心结论

  • 9vHPV疫苗在35岁及以下HIV感染的MSM中显示稳健免疫原性和令人鼓舞的病毒清除率,支持将该高危人群接种年龄扩展至26岁以上。

研究设计与样本

  • IV期开放标签单臂多中心临床试验,入组158例、符合方案分析138例,受试者为16-35岁HIV感染MSM,病毒载量检测不到且CD4计数>200 cells/mm³。
  • 受试者在第0、8、24周接种9vHPV疫苗,随访至第96周,基线和第28周、第96周采集血清免疫原性、肛周HPV DNA检测和不良事件报告。

主要发现

  • 第96周时九个HPV疫苗基因型血清转换率均超过85%。
  • 疫苗包含基因型的新发感染发生于24%的受试者,以HPV-16为主。
  • 疫苗包含的任何高危HPV基因型总体清除率在第96周为74%。
  • 年龄≥26岁、较低CD4/CD8比值、最低CD4或CD4计数均不影响免疫原性。
  • 未记录与接种相关的严重不良事件。

临床怎么用

  • 在HIV感染的MSM中,9vHPV疫苗可考虑用于26岁以上至35岁人群,以提供九价配方的额外覆盖。
  • 接种后仍需关注HPV-16等疫苗型别的新发感染,并监测高危型HPV清除情况。

局限性

  • 单臂设计,缺乏对照组。
  • 符合方案分析仅纳入138/158例入组受试者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men who have sex with men (MSM) with HIV are at increased risk for anal cancer, largely attributable to persistent HPV infection. However, data on the nonavalent HPV vaccine (9vHPV) in MSM with HIV older than 26 remain sparse. METHODS: This phase IV trial evaluated the immunogenicity, safety, and impact of age and CD4/CD8 ratio on 9vHPV vaccine responses in MSM with HIV up to 35 years. Inclusion criteria were age 16-35, undetectable viral load, and CD4 + counts >200 cells/mm³. Participants received 9vHPV vaccine doses at weeks 0, 8, and 24, and were followed to week 96. Serum samples for immunogenicity, anal HPV DNA testing, and adverse event reports were collected at baseline, week 28, and week 96. Additionally, we investigated potential predictors of vaccine immunogenicity, including age group and CD4/CD8 ratio. RESULTS: Among 158 enrolled participants, 138 completed the per-protocol analysis. Seroconversion exceeded 85% for all nine HPV vaccine genotypes at week 96. New infections with vaccine-included genotypes occurred in 24% of participants, predominantly involving HPV-16. The overall clearance rate for any high-risk HPV genotype included in the vaccine was 74% at week 96. Neither older age (≥26 years), lower CD4/CD8 ratio, nadir CD4 or CD4 counts affected immunogenicity. No severe adverse events related to vaccination were recorded. CONCLUSIONS: The 9vHPV vaccine demonstrated robust immunogenicity and encouraging viral clearance rates in MSM with HIV up to 35 years. These findings support extending vaccination beyond 26 years in this high-risk group, emphasizing the additional coverage provided by the 9vHPV formulation. CLINICAL TRIAL REGISTRATION: EudraCT number 2018-000215-24.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ron R, Díaz-García C, Sendagorta E, et al. A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017. Clin Infect Dis. 2026. PMID: 40794702. doi:10.1093/cid/ciaf435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。